Lilly launches the "Changing the Thread Collection" with Tan France

Eli Lilly announced on November 10 a marketing campaign for Zepbound (tirzepatide) called the "Changing the Thread Collection," featuring clothing embroidered with stories from people who have used the drug, fronted by "Queer Eye" stylist Tan France ^[1][2]. The company describes it as the first collection of its kind, meant to use clothing as "a canvas for sharing the science, the struggles and the accomplishments along an obesity journey" ^[1][2].

The pieces range from scrubs to a swimsuit, each stitched with a real patient's account ^[1][2]. One story France said stayed with him involved a black puffer vest worn almost nine months a year, everywhere from work meetings to dates, as a way to hide from judgment ^[1][2]. The campaign's website features videos of patients tied to specific garments, including a swimsuit story from a person named Antequa, a gray jacket from Samantha, and scrubs from Kevin, with participants describing obesity as "a real disease" ^[3]. Visitors can also take a quiz called "What Kind of Threadsetter Are You?" that assigns results like "The Challenger" or "Quiet Force" tied to ways of pushing back on obesity stigma ^[3].

Lilly is staging an in-person version of the campaign at 13 Crosby Street in New York City on November 14 and 15, from 1 p.m. to 8 p.m., where the embroidered garments will be on display ^[1][2][3]. France, who says he does not take Zepbound and was compensated for his participation, called himself "an advocate for every body" and said the goal is to help people "seek obesity care without fear" ^[1][2][3]. He is not Lilly's first celebrity partner for the drug: actress Kym Whitley became Zepbound's first celebrity spokesperson earlier this summer, also sharing her own account of taking the medicine ^[3].

Why it matters for patients

This is marketing, not new clinical information. The campaign does not change Zepbound's approved uses, dosing, or safety profile. Lilly's own materials still list the same warnings that accompany every Zepbound prescription, including possible thyroid tumors, severe stomach problems, dehydration, gallbladder problems, pancreatitis, serious allergic reactions, low blood sugar in combination with certain diabetes medicines, vision changes, and mood changes including thoughts of suicide ^[1][2].

For patients and their families, the practical value of the campaign is mostly about tone: it is an attempt by the drug's maker to reduce social stigma around obesity treatment by reframing it as chronic disease care rather than a matter of willpower ^[1][2][3]. Whether that message changes how people are treated by employers, doctors, or family members is not something the sources address, and no independent research is cited on the campaign's actual effect on stigma.

The campaign also arrives alongside broader news about Zepbound's price and access. Lilly has been rolling out direct-to-consumer discounts for self-pay patients and, following an agreement with the White House, a $50-per-month price for some Medicare patients ^[3]. Health and Human Services Secretary Robert F. Kennedy Jr. said at a November 6 press conference that he expects Americans to "lose 125 million pounds by this time next year" because of the pricing deals Lilly and Novo Nordisk struck with the government, a claim reported by FiercePharma but not something the sources independently verify ^[3].

What happens next

The Changing the Thread pop-up runs November 14 and 15 in New York City ^[1][2][3]. Beyond the event dates and the ongoing rollout of Zepbound's new pricing arrangements, the sources do not describe any additional scheduled milestones for the campaign itself.